France Drug Delivery Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.20 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
France Drug Delivery Devices Market Analysis
The French drug delivery devices market is anticipated to expand at a CAGR of 5.2% over the forecast period.
With the emergence of the COVID-19 pandemic, most pharmaceutical companies and governments have been/are working to provide adequate medical therapy to COVID-19 patients, and drug delivery devices are likely to play an essential role in this context. For example, large-scale vaccination programs are being implemented worldwide to immunize people against the SARS-COV-2 virus. However, many companies are still working on more efficient ways of delivering COVID-19 therapeutics to patients and are investing heavily in it, which is expected to impact the drug delivery market significantly. For instance, in January 2022, the BioMAP research team from the Infectiology and Public Health (ISP) joint research unit run by INRAE and the Université de Tours developed a protein vaccine candidate for nasal administration to project against COVID-19 blocking all transmission of the virus. The Ministry of Higher Education, Research, and innovation supports the project and is accompanied by the National Agency for AIDS Research (ANRS). As a result, COVID-19 was predicted to impact the drug delivery market's growth substantially. Additionally, the market is anticipated to resume its rise during the projection period as more research and development is undertaken on COVID-19 vaccines and all restrictions are removed.
The rising prevalence of chronic diseases, technological advancements, and growth in the biologics market are some key factors driving the development of the France drug delivery devices market. Many disorders, including cardiovascular disease and diabetes, can benefit from targeted drug administration. The most important application of targeted medication delivery is the treatment of malignant tumors. As a result, the increasing prevalence of these disorders is likely to drive market expansion throughout the forecast period. For instance, the high burden of cancer can be explained by the latest statistics provided by the International Agency for Research on Cancer published GLOBOCAN 2020 report, which stated that in 2020, there were an estimated 467,965 new cancer cases diagnosed, where the male population accounted for 260,169 cases followed by female population with 207,796 cases. This shows a high burden of cancer among the target population. As a result, the population's increasing reliance on various drug types, including chemotherapy and intravenous therapy, is projected to fuel the market's expansion.
Thus, all the mentioned factors are expected to boost market growth over the forecast period. However, the risk of needlestick injury may restrain market growth over the forecast period.
France Drug Delivery Devices Market Trends
This section covers the major market trends shaping the France Drug Delivery Devices Market according to our research experts:
Diabetes Segment is Estimated to Witness Healthy Growth over the Forecast Period
The diabetes segment is driven by the increasing prevalence of diabetes in France and the product launches by the key market players. According to the International Diabetes Federation, in February 2022, the diabetic majority was 8.6%, with 3,942,900 adult diabetics in France in 2020. Additionally, according to the World Health Organization (WHO) May 2021, about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, unhealthy diets, and sedentary lifestyles. Thus, the rising prevalence of diabetes and obesity, growing awareness regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that further drive the segment in France.
Furthermore, strategies adopted by the key market players, such as product launches, mergers, acquisitions, and partnerships, are likely to support market growth. For instance, in April 2021, BioCorp and Roche Diabetes Care France reported the launch of the Mallya smart insulin pen device in France. The device is designed to automatically gather insulin data (dose, date, and time) and upload it to Roche's Gluci-Chek application to ensure qualified information on which the patient can depend and the clinician may utilize to make informed clinical decisions. Additionally, in November 2021, Sanofi and Roche joined forces in France, teaming up to drive the adoption of a connected add-on for disposable insulin pens. The partners will jointly develop a scientific program for physicians and retail pharmacists around the Biocorp product. Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.
Infectious Diseases is Expected to Hold Significant Share During the Forecast Period
Pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi, cause infectious diseases. These diseases can spread directly or indirectly from one person to another. Common contagious diseases are Streptococcal Pharyngitis, urinary tract infections (caused by bacteria), HIV/AIDS, the common cold (caused by a virus), Athlete's foot (a common fungus), etc.
With the increasing burden of infectious diseases in France, the market is expected to project growth over the forecast period. According to the UNAIDS factsheet, in 2021, there were 190,000 HIV-positive persons in France. In 2021, the number of new HIV infections was 5,800. Regarding gender, men are more impacted than women, and it is most common among people aged 55 to 64. The region of Paris, known as Île-de-France, has the highest rate of diagnoses. Thus, the country's growing prevalence of infectious diseases is expected to increase demand for drug-delivery devices, thereby boosting the market's growth over the forecast period.
Additionally, various initiatives the market players take are likely to support the market's growth over the forecast period. For instance, in November 2022, Aptar Pharma, a drug delivery company, completed the first phase of its announced USD 180 million expansion initiative to satisfy expanding customer capacity needs for injectable system solutions.
Thus, all factors above such as the growing prevalence of infectious diseases and strategic initiatives by market players, are expected to boost the market in the country over the forecast period.
France Drug Delivery Devices Industry Overview
The French drug delivery devices Market is moderately competitive and consists of several major players. Some companies currently dominating the market are Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Inc, Becton, Dickinson and Company, and 3M, among others.
France Drug Delivery Devices Market Leaders
-
Becton, Dickinson and Company
-
Baxter International Inc.
-
Teva Pharmaceutical Industries Ltd
-
Novartis Inc.
-
3 M company
*Disclaimer: Major Players sorted in no particular order
France Drug Delivery Devices Market News
- September 2022: Biocorp, a French company specializing in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of the SoloSmart Injection Pen.
- July 2022: EVEON announced the launch of the INDENEO European consortium project for the Uncommon Disease Research (RDR) Challenge Call to develop a delivery system from the nose to the brain to treat rare central nervous system (CNS) illnesses such as encephalitis in neonates.
France Drug Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increased Prevalence of Chronic Diseases
- 4.2.2 Technological Advances
-
4.3 Market Restraints
- 4.3.1 Risk of Needlestick Injuries
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size By Value - USD million)
-
5.1 By Route of Administration
- 5.1.1 Injectable
- 5.1.2 Topical
- 5.1.3 Other Routes of Administration
-
5.2 By Application
- 5.2.1 Cancer
- 5.2.2 Cardiovascular
- 5.2.3 Diabetes
- 5.2.4 Infectious diseases
- 5.2.5 Other Applications
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Ambulatory Centers
- 5.3.3 Other End Users
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 3M
- 6.1.2 Baxter International
- 6.1.3 Bayer AG
- 6.1.4 F. Hoffmann-La Roche AG
- 6.1.5 GlaxoSmithKline PLC
- 6.1.6 Johnson & Johnson
- 6.1.7 Merck & Co.
- 6.1.8 Novartis AG
- 6.1.9 Pfizer Inc
- 6.1.10 Sanofi
- 6.1.11 Becton, Dickinson and Company
- 6.1.12 Teva Pharmaceutical
- 6.1.13 Viatris Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
France Drug Delivery Devices Industry Segmentation
As per the scope of the report, drug delivery devices or systems are the tools that are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The market is segmented by route of administration (injectable, topical, and other routes of administration), application (cancer, cardiovascular, diabetes, infectious diseases, and other applications), and end user (hospitals, ambulatory surgical centers, and other end users). The report offers the value (in USD million) for the above segments.
| By Route of Administration | Injectable |
| Topical | |
| Other Routes of Administration | |
| By Application | Cancer |
| Cardiovascular | |
| Diabetes | |
| Infectious diseases | |
| Other Applications | |
| By End User | Hospitals |
| Ambulatory Centers | |
| Other End Users |
France Drug Delivery Devices Market Research FAQs
What is the current France Drug Delivery Devices Market size?
The France Drug Delivery Devices Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in France Drug Delivery Devices Market?
Becton, Dickinson and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd, Novartis Inc. and 3 M company are the major companies operating in the France Drug Delivery Devices Market.
What years does this France Drug Delivery Devices Market cover?
The report covers the France Drug Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the France Drug Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
France Drug Delivery Devices Industry Report
Statistics for the 2024 France Drug Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. France Drug Delivery Devices analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
